Vicadrostat is a potent, highly selective aldosterone synthase inhibitor in clinical development in combination with the SGLT2i empagliflozin (VicaEmpa) for treatment of CKD and heart failure. The gene discussed is CYP11B2; the disease is chronic kidney disease.